Entrada Therapeutics Announces ENTR-501 for the Treatment of Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)
January 8, 2020
Entrada Therapeutics, Inc. a biotechnology company dedicated to transforming the treatment of devastating diseases through the intracellular delivery of biologics, today announced that it is developing ENTR-501, a novel thymidine phosphorylase enzyme replacement therapy, for the treatment of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE).
ENTR-501 is a recombinant form of the thymidine phosphorylase enzyme engineered using Entrada’s proprietary Endosomal Escape Vehicle (EEV) technology and is designed to replace deficient thymidine phosphorylase in MNGIE patients.
Full press release here